Clinical Trial Update: A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-finding study of TKM-080301 infusion in neuroendocrine tumors and adrenocortical carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Neuroendocrine Tumors

Drugs mentioned

• TKM-080301

Snippet

Sponsor: Arbutus Biopharma Corporation | Conditions: Cancer, Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED